Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lifetime Manipulation by Excitation Power in Lanthanide Core-Shell Nanocrystals Without Altering Composition.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Inoculation with Lactobacillus rhamnosus improves fermentation quality of napier grass silage by enriching Lactobacillus buchneri in tropical regions.

BMC plant biology·2026
Same author

Dual-energy CT-derived fibrosis biomarkers predict pancreatic fistula after pancreaticoduodenectomy: a collagen proportional area mediation analysis.

European journal of radiology·2026
Same author

Asporin promotes gastric cancer progression by regulating NRF2 ubiquitination and competitively binding to KEAP1.

Translational cancer research·2026
Same author

Macroecological processes impact Australian soil resistomes and climatically stable regions with anthropogenic activities serve as ARG hotspots.

The ISME journal·2026
Same author

Nitrogen vacancies g-C<sub>3</sub>N<sub>4</sub>/BiOBr S-scheme heterojunction with Pd for efficient photocatalytic H<sub>2</sub>O<sub>2</sub>production.

Nanotechnology·2026

Related Experiment Video

Updated: Feb 24, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Micron-Scale 2D Antibody Arrays for HER2 Signaling Blockade and Cancer Therapy.

Mingming Du1, Xiang Zhong1, Tingfeng Yao1

  • 1CAS Key Laboratory of Nano-Bio Interface, Jiangsu Key Laboratory of Organoid Engineering and Precision Medicine, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China.

Journal of the American Chemical Society
|February 23, 2026
PubMed
Summary

This study introduces RhuA-P, a novel protein platform that creates 2D antibody arrays. These arrays enhance cancer therapy by blocking HER2 receptor signaling, leading to improved antitumor efficacy.

More Related Videos

Flow-pattern Guided Fabrication of High-density Barcode Antibody Microarray
09:05

Flow-pattern Guided Fabrication of High-density Barcode Antibody Microarray

Published on: January 6, 2016

21.0K
Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions
06:01

Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions

Published on: January 7, 2019

7.7K

Related Experiment Videos

Last Updated: Feb 24, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Flow-pattern Guided Fabrication of High-density Barcode Antibody Microarray
09:05

Flow-pattern Guided Fabrication of High-density Barcode Antibody Microarray

Published on: January 6, 2016

21.0K
Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions
06:01

Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions

Published on: January 7, 2019

7.7K

Area of Science:

  • Biotechnology
  • Cancer Biology
  • Immunotherapy

Background:

  • Monoclonal antibodies (mAbs) targeting human epidermal growth factor receptor 2 (HER2) are crucial for treating solid tumors.
  • Rapid HER2 endocytosis and recycling limit the efficacy of current HER2-targeted therapies, contributing to resistance.

Purpose of the Study:

  • To develop a novel protein-based platform, RhuA-P, for creating spatially controlled 2D antibody arrays.
  • To investigate the therapeutic potential of RhuA-P-templated trastuzumab (TmAb) arrays in enhancing HER2-targeted cancer therapy.

Main Methods:

  • RhuA-P self-assembly into uniform micron-sized 2D arrays with Protein G sites for mAb conjugation.
  • Control over antibody density and intermolecular spacing on the arrays.
  • In vitro assays to assess HER2 dimerization, clustering, endocytosis blockade, and apoptosis induction.
  • In vivo evaluation of TmAb array efficacy in a murine breast cancer model.

Main Results:

  • RhuA-P arrays enabled precise control over TmAb density and spacing.
  • TmAb arrays effectively inhibited HER2 dimerization and clustered HER2 into inactive domains.
  • Arrays prolonged HER2 membrane retention by blocking endocytosis, inducing oxidative stress and apoptosis.
  • TmAb arrays demonstrated superior antitumor efficacy compared to free TmAb in a preclinical model.

Conclusions:

  • RhuA-P is a versatile platform for assembling antibody arrays, offering a generalized strategy to enhance antibody-based therapies.
  • Spatially controlled antibody arrays can overcome limitations of free mAbs by modulating receptor dynamics and signaling.
  • This approach holds promise for improving treatment outcomes in HER2-positive cancers and potentially other antibody-treatable diseases.